Target identification for a Hedgehog pathway inhibitor reveals the receptor GPR39

Nature Chemical Biology

Volumn 10, Issue 5, 2014, Pages 343-349

  Bassilana, Frederic ^a   Carlson, Adam ^b   Dasilva, Jennifer A ^b   Grosshans, Bianka ^a   Vidal, Solange ^a   Beck, Valerie ^a   Wilmeringwetter, Barbara ^a   Llamas, Luis A ^b   Showalter, Todd B ^b   Rigollier, Pascal ^a   Bourret, Aaron ^b   Ramamurthy, Arun ^b   Wu, Xu ^c,e   Harbinski, Fred ^b   Plonsky, Samantha ^b   Lee, Lac ^b   Ruffner, Heinz ^d,e   Grandi, Paola ^d   Schirle, Markus ^d   Jenkins, Jeremy ^b   Sailer, Andreas W ^a   Bouwmeester, Tewis ^d   Porter, Jeffrey A ^b   Myer, Vic ^b   Finan, Peter M ^b   Tallarico, John A ^b   Kelleher, Joseph F ^b   Seuwen, Klaus ^a   Jain, Rishi K ^b   Luchansky, Sarah J ^b   more..

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE; COMPLEMENTARY DNA; G PROTEIN COUPLED RECEPTOR; INOSITOL PHOSPHATE; MESSENGER RNA; METHYL GROUP; PROTEIN GPR39; PYRIMIDINE DERIVATIVE; RECEPTOR PROTEIN; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL FATE; CONTROLLED STUDY; GENE EXPRESSION; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ERINACEIDAE;

CHROMATOGRAPHY, AFFINITY; HEDGEHOG PROTEINS; PROTEOMICS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY;

EID: 84899482439     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1481     Document Type: Article

References (50)

1. Ingham, P.W., Nakano, Y. & Seger, C. Mechanisms and functions of Hedgehog signalling across the metazoa. Nat. Rev. Genet. 12, 393-406 (2011).
2. Jiang, J. & Hui, C.C. Hedgehog signaling in development and cancer. Dev. Cell 15, 801-812 (2008).
3. Rubin, L.L. & de Sauvage, F.J. Targeting the Hedgehog pathway in cancer. Nat. Rev. Drug Discov. 5, 1026-1033 (2006). (Pubitemid 44835129)
4. Hahn, H. et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85, 841-851 (1996). (Pubitemid 26192135)
5. Xie, J. et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 391, 90-92 (1998). (Pubitemid 28079221)
6. Taylor, M.D. et al. Mutations in SUFU predispose to medulloblastoma. Nat. Genet. 31, 306-310 (2002).
7. Northcott, P.A. et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat. Genet. 41, 465-472 (2009).
8. Pastorino, L. et al. Identification of a SUFU germline mutation in a family with Gorlin syndrome. Am. J. Med. Genet. A 149A, 1539-1543 (2009).
9. Northcott, P.A. et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 488, 49-56 (2012).
10. Ragazzini, P. et al. Amplification of CDK4, MDM2, SAS and GLI genes in leiomyosarcoma, alveolar and embryonal rhabdomyosarcoma. Histol. Histopathol. 19, 401-411 (2004). (Pubitemid 38443902)
11. Kinzler, K.W. et al. Identification of an amplified, highly expressed gene in a human glioma. Science 236, 70-73 (1987). (Pubitemid 17056814)
12. Skvara, H. et al. Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor. J. Invest. Dermatol. 131, 1735-1744 (2011).
13. Low, J.A. & de Sauvage, F.J. Clinical experience with Hedgehog pathway inhibitors. J. Clin. Oncol. 28, 5321-5326 (2010).
14. Buonamici, S. et al. Interfering with resistance to smoothened antagonists by inhibition of the pi3k pathway in medulloblastoma. Sci. Transl. Med. 2, 1-8 (2010).
15. Yauch, R.L. et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 326, 572-574 (2009).
16. Metcalfe, C. & de Sauvage, F.J. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. Cancer Res. 71, 5057-5061 (2011).
17. Dijkgraaf, G.J. et al. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res. 71, 435-444 (2011).
18. Miller-Moslin, K. et al. 1-Amino-4-benzylphthalazines as orally bioavailable smoothened antagonists with antitumor activity. J. Med. Chem. 52, 3954-3968 (2009).
19. Frank-Kamenetsky, M. et al. Small-molecule modulators of Hedgehog signaling: identification and characterization of Smoothened agonists and antagonists. J. Biol. 1, 10 (2002).
20. Chen, J.K., Taipale, J., Cooper, M.K. & Beachy, P.A. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev. 16, 2743-2748 (2002). (Pubitemid 35253140)
21. Romer, J.T. et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1+/? p53?/? mice. Cancer Cell 6, 229-240 (2004). (Pubitemid 39222036)
22. Peukert, S. et al. Discovery of NVP-LEQ506, a second-generation inhibitor of Smoothened. ChemMedChem 8, 1261-1265 (2013).
23. Nachtergaele, S. et al. Oxysterols are allosteric activators of the oncoprotein Smoothened. Nat. Chem. Biol. 8, 211-220 (2012).
24. Huang, S.M. et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461, 614-620 (2009).
25. Nidhi Glick, M., Davies, J.W. & Jenkins, J.L. Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases. J. Chem. Inf. Model. 46, 1124-1133 (2006). (Pubitemid 43999157)
26. Waschek, J.A., Dicicco-Bloom, E., Nicot, A. & Lelievre, V. Hedgehog signaling: new targets for GPCRs coupled to cAMP and protein kinase A. Ann. NY Acad. Sci. 1070, 120-128 (2006). (Pubitemid 44126629)
27. Lelievre, V. et al. Disruption of the PACAP gene promotes medulloblastoma in ptc1 mutant mice. Dev. Biol. 313, 359-370 (2008). (Pubitemid 350298324)
28. Newman-Tancredi, A., Cussac, D., Marini, L. & Millan, M.J. Antibody capture assay reveals bell-shaped concentration-response isotherms for h5-HT1A receptor-mediated G?i3 activation: conformational selection by high-efficacy agonists, and relationship to trafficking of receptor signaling. Mol. Pharmacol. 62, 590-601 (2002). (Pubitemid 36329377)
29. Depoortere, I. GI functions of GPR39: novel biology. Curr. Opin. Pharmacol. 12, 647-652 (2012).
30. Popovics, P. & Stewart, A.J. GPR39: a Zn2+-activated G protein-coupled receptor that regulates pancreatic, gastrointestinal and neuronal functions. Cell. Mol. Life Sci. 68, 85-95 (2011).
31. Moechars, D. et al. Altered gastrointestinal and metabolic function in the GPR39-obestatin receptor-knockout mouse. Gastroenterology 131, 1131-1141 (2006). (Pubitemid 44498686)
32. Egerod, K.L. et al. ?-cell specific overexpression of GPR39 protects against streptozotocin-induced hyperglycemia. Int. J. Endocrinol. 2011, 401258 (2011).
33. Holst, B. et al. G protein-coupled receptor 39 deficiency is associated with pancreatic islet dysfunction. Endocrinology 150, 2577-2585 (2009).
34. Petersen, P.S. et al. Deficiency of the GPR39 receptor is associated with obesity and altered adipocyte metabolism. FASEB J. 25, 3803-3814 (2011).
35. Tremblay, F. et al. Disruption of G protein-coupled receptor 39 impairs insulin secretion in vivo. Endocrinology 150, 2586-2595 (2009).
36. Verhulst, P.J. et al. GPR39, a receptor of the ghrelin receptor family, plays a role in the regulation of glucose homeostasis in a mouse model of early onset diet-induced obesity. J. Neuroendocrinol. 23, 490-500 (2011).
37. Zhang, J.V. et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 310, 996-999 (2005). (Pubitemid 41611907)
38. Holst, B. et al. GPR39 signaling is stimulated by zinc ions but not by obestatin. Endocrinology 148, 13-20 (2007). (Pubitemid 46021433)
39. Dong, X.Y. et al. Is GPR39 the natural receptor of obestatin? Peptides 30, 431-438 (2009).
40. Yasuda, S. et al. Isolation of Zn2+ as an endogenous agonist of GPR39 from fetal bovine serum. J. Recept. Signal Transduct. Res. 27, 235-246 (2007). (Pubitemid 47450769)
41. Markus, B. et al. Chemical probe identification platform for orphan GPCRs using focused compound screening: GPR39 as a case example. ACS Med. Chem. Lett. 4, 1079-1084 (2013).
42. Lauth, M., Bergstrom, A. & Toftgard, R. Phorbol esters inhibit the Hedgehog signalling pathway downstream of Suppressor of Fused, but upstream of Gli. Oncogene 26, 5163-5168 (2007). (Pubitemid 47206952)
43. Atwood, S.X., Li, M., Lee, A., Tang, J.Y. & Oro, A.E. GLI activation by atypical protein kinase Ci/? regulates the growth of basal cell carcinomas. Nature 494, 484-488 (2013).
44. Axelrod, M. et al. Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms. Oncotarget 4, 622-635 (2013).
45. Ji, Z., Mei, F.C., Xie, J. & Cheng, X. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. J. Biol. Chem. 282, 14048-14055 (2007). (Pubitemid 47100411)
46. Fogarty, M.P., Emmenegger, B.A., Grasfeder, L.L., Oliver, T.G. & Wechsler-Reya, R.J. Fibroblast growth factor blocks Sonic hedgehog signaling in neuronal precursors and tumor cells. Proc. Natl. Acad. Sci. USA 104, 2973-2978 (2007). (Pubitemid 46327988)
47. Berridge, M.J., Downes, C.P. & Hanley, M.R. Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem. J. 206, 587-595 (1982). (Pubitemid 13199531)
48. Seuwen, K., Lagarde, A. & Pouyssegur, J. Deregulation of hamster fibroblast proliferation by mutated ras oncogenes is not mediated by constitutive activation of phosphoinositide-specific phospholipase C. EMBO J. 7, 161-168 (1988).
49. Berridge, M.J. & Irvine, R.F. Inositol phosphates and cell signalling. Nature 341, 197-205 (1989). (Pubitemid 19231718)
50. Salomon, Y. Adenylate cyclase assay. Adv. Cycl. Nucleot. Res. 10, 35-55 (1979).